Tag: PB2452
PhaseBio receives FDA breakthrough therapy designation for PB2452 for the reversal of the antiplatelet activity of ticagrelor
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) has announced that the US FDA has granted breakthrough...
